Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- Cylinder Health strengthens gut-brain leadership with new Head of Gut-Brain Health and Clinical Advisory Board appointment (Cylinder Health)
- The new era of physician independence (Medical Economics)
- “Don’t Take Shortcuts,” Endoscopy Researcher Advises (GI & Hepatology News)
- Olympus Unveils Corporate Strategy (Olympus)
- Unlocking value creation in healthcare: How AI can reverse private equity’s return challenges – Part 1: HealthTech and tech-enabled services (Lexology)
- 5 highest-paid gastroenterologists in New York City (Becker’s GI & Endoscopy)
- And Your 2025 Healio Disruptive Innovators Are … (Healio)
- The Hype and Limits of At-Home Gut Microbiome Tests (U.S. News)
